EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSCATG00000012832
Gene Symbol: DHCR24
4 Cross references
209 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

26s Protease Regulatory Subunit 10b Pseudogene

Ensembl ID : ENSCATG00000031604
Gene Symbol: LOC105599587
1 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

26s Protease Regulatory Subunit 6a Pseudogene

Ensembl ID : ENSCATG00000033940
Gene Symbol: LOC105592490
1 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSCATG00000014646
Gene Symbol: HMGCR
4 Cross references
272 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSCATG00000032981
Gene Symbol: PDPK1
4 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSCATG00000031436
Gene Symbol: HPD
4 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12

Ensembl ID : ENSCATG00000041611
Gene Symbol: LOC105592751
2 Cross references
136 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12 Pseudogene

Ensembl ID : ENSCATG00000009325
Gene Symbol: LOC105582846
1 Cross references
136 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S12-Like

Ensembl ID : ENSCATG00000038780
Gene Symbol: LOC105582265
2 Cross references
175 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S13

Ensembl ID : ENSCATG00000044705
Gene Symbol: LOC105589055
2 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S13 Pseudogene

Ensembl ID : ENSCATG00000018658
Gene Symbol: LOC105586253
1 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

40s Ribosomal Protein S20 Pseudogene

Ensembl ID : ENSCATG00000020059
Gene Symbol: LOC105591970
1 Cross references
149 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).